Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Found vs Direct Meds

Two GLP-1 desks, one scoreboard. We put Found and Direct Meds head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 5 · Grade B+

Found

Visit Found Full brief →
vs
No. 28 · Grade B−

Direct Meds

Visit Direct Meds Full brief →

The verdict

Found takes this head-to-head.

Found scores 88 to 82 on our six-factor Brief Score — A coaching-first program with the lowest identical price on both molecules — if you want the coaching lock-in that comes with it.

That doesn't make Direct Meds a bad call — it's best for readers who want a needle-free oral or sublingual route on either molecule and an all-inclusive price with no separate membership — and who are comfortable that the figures are company-stated rather than checkout-verified. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
88
80
Supply Reliability
88
80
Transparency
88
78
Access Breadth
88
84
Clinical Oversight
90
83
Track Record
86
78
FoundBrief Score 88 · 82Direct Meds

Price, coverage & the tracker

FoundDirect Meds
Brief Score88/100 (B+)82/100 (B−)
Semaglutide$129/mo$179/mo
Tirzepatide$129/mo$224/mo
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Found: Lowest identical-price line on the board — but bundled into a coaching subscription.

Direct Meds: Company-stated rates unchanged this cycle — but we price these off the desk's own listings, not a live-verified checkout, so treat them as indicative.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.